<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-related <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-inducing ligand (TRAIL) has been considered as a possible therapeutic agent for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatment </plain></SENT>
<SENT sid="1" pm="."><plain>This is because of its selective cytotoxicity against various <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells without a detrimental effect on <z:mpath ids='MPATH_458'>normal</z:mpath> cells </plain></SENT>
<SENT sid="2" pm="."><plain>However, recent studies have reported that the potential application of TRAIL in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy is limited, as many <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells have been found to be resistant to TRAIL </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, small molecule compounds that potentiate the cytotoxicity of TRAIL would be strategic candidates for therapeutic applications in combination with TRAIL </plain></SENT>
<SENT sid="4" pm="."><plain>Here we found that a combined treatment of inostamycin and TRAIL synergistically induced caspase-dependent <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in HCT116 cells </plain></SENT>
<SENT sid="5" pm="."><plain>Inostamycin upregulated DR5, and a knockdown of DR5 suppressed the <z:mpath ids='MPATH_3'>apoptosis</z:mpath> that was synergistically induced by co-treatment with inostamycin and TRAIL </plain></SENT>
<SENT sid="6" pm="."><plain>Moreover, inostamycin increased the expression of DR5 on the cell surface </plain></SENT>
<SENT sid="7" pm="."><plain>Therefore, inostamycin-increased cell surface expression of DR5 may have contributed to the enhancement of TRAIL-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain>Our study suggests that combined treatment with inostamycin and TRAIL may offer a strategy to overcome TRAIL resistance in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
</text></document>